Anderson, D., Spybrook, J. and Maynard, R. (2019) ‘REES: A registry of efficacy and effectiveness studies in education’, Educational Researcher, 48(1), pp. 45–50. https://doi.org/10.3102/0013189X18810513.
ClinicalTrials.gov (2018) Why Should I Register and Submit Results? Available at: https://clinicaltrials.gov/ct2/manage-recs/background (Accessed: 20 May 2019).
Doshi, P. (2015) ‘No correction, no retraction, no apology, no comment: Paroxetine trial reanalysis raises questions about institutional responsibility’, BMJ (Online), 351(September), p. h4629. https://doi.org/10.1136/bmj.h4629.
FDA (2007) Food and Drug Administration Amendments Act of 2007, Public Law 110-85. USA. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf (Accessed: 13 May 2019).
Franco, A., Malhorta, N. and Simonvits, G. (2014) ‘Publication bias in the social sciences: Unlocking the file drawer’, Science, 345(6203), pp. 1502–1506. https://doi.org/10.1126/science.1255484.
Goldacre, B., Drysdale, H., Powell-Smith, A., Dale, A., et al. (2016) The COMPare Trials Project. Available at: http://compare-trials.org/ (Accessed: 21 May 2019).
Hedin, R. J., Umberham, B. A., Detweiler, B. N., Kollmorgen, L., et al. (2016) ‘Publication Bias and Nonreporting Found in Majority of Systematic Reviews and Meta-analyses in Anesthesiology Journals’, Anesthesia and Analgesia, 123(4), pp. 1018–1025. https://doi.org/10.1213/ANE.0000000000001452.
Hopewell, S., Loudon, K., Mj, C., Ad, O., et al. (2009) ‘Publication bias in clinical trials due to statistical significance or direction of trial results (Review)’, Cochrane Database of Systematic Reviews, (1), p. MR000006. https://doi.org/10.1002/14651858.MR000006.pub3.
Joober, R., Schmitz, N., Annable, L. and Boksa, P. (2012) ‘Publication bias: What are the challenges and can they be overcome?’, Journal of Psychiatry and Neuroscience, 37(3), pp. 149–152. https://doi.org/10.1503/jpn.120065.
Mlinarić, A., Horvat, M. and Smolčić, V. Š. (2017) ‘Dealing with the positive publication bias: Why you should really publish your negative results’, Biochemia Medica, 27(3), p. 030201. https://doi.org/10.11613/BM.2017.030201.
Mulder, R., Rucklidge, J. J. and Toop, L. (2016) ‘Restoring Study 329: Paroxetine neither effective nor safe for adolescents’, Australian and New Zealand Journal of Psychiatry, 50(9), pp. 922–923. https://doi.org/10.1177/0004867416657412.
Le Noury, J., Nardo, J. M., Healy, D., Jureidini, J., et al. (2015) ‘Restoring Study 329: Eficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence’, BMJ (Online), 351, p. h4320. https://doi.org/10.1136/bmj.h4320.
Sterling, T. D. (1959) ‘Publication decisions and their possible effects on inferences drawn from tests of significance - or vice versa’, Journal of the American Statistical Association, 54(285), pp. 30–34. https://doi.org/10.2307/2282137.
Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., et al. (2004) ‘Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data’, Lancet, 363(9418), pp. 1341–1345. https://doi.org/10.1016/S0140-6736(04)16043-1.
Zarin, D. A., Tse, T., Ph, D., Williams, R. J., et al. (2016) ‘Trial reporting in ClinicalTrials.gov — The Final Rule’, New England Journal of Medicine, 375(20), pp. 1998–2004. https://doi.org/10.1056/NEJMsr1611785.
Zarin, D. A., Tse, T., Williams, R. J. and Rajakannan, T. (2017) ‘Update on trial registration 11 years after the ICMJE Policy was established’, New England Journal of Medicine, 376(4), pp. 383–391. https://doi.org/10.1056/nejmsr1601330.